PHIO PHARMACEUTICALS CORP (PHIO)

Company Profile

Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics. The company is headquartered in Marlborough, Massachusetts and currently employs 9 full-time employees. The company went IPO on 2012-05-10. The firm is focused on developing immuno-oncology therapeutics based on its self-delivering ribonucleic acid interface (RNAi) INTASYL therapeutic platform. Its INTASYL compounds are designed to precisely target specific proteins that reduce the body’s ability to fight cancer without the need for specialized formulations or drug delivery systems, and are designed to make immune cells effective in killing tumor cells. Its lead product candidate, PH-762, is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. Its second product candidate, PH-894, is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby effecting the immune system as well as the tumor.

Company Info

PHIO PHARMACEUTICALS CORP

257 Simarano Dr Ste 101

Marlborough MASSACHUSETTS 01752

P: 15087673861

CEO: Gerrit Dispersyn

Employees: 9

Website: https://phiopharma.com/